[HTML][HTML] Anticancer drug resistance: An update and perspective
Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …
can inhibit the action of the mutant protein; however, drug resistance almost invariably …
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
A Leonetti, S Sharma, R Minari, P Perego… - British journal of …, 2019 - nature.com
Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the …
tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the …
Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
Tyrosine kinase inhibitors were found to be clinically effective for treatment of patients with
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …
EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research
RF Dong, ML Zhu, MM Liu, YT Xu, LL Yuan… - Pharmacological …, 2021 - Elsevier
With the development of precision medicine, molecular targeted therapy has been widely
used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal …
used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal …
IL6 mediates suppression of T-and NK-cell function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Purpose: Patients with advanced non–small cell lung cancer (NSCLC) harboring activating
EGFR mutations are initially responsive to tyrosine kinase inhibitors (TKI). However …
EGFR mutations are initially responsive to tyrosine kinase inhibitors (TKI). However …
Fighting drug resistance through the targeting of drug-tolerant persister cells
G De Conti, MH Dias, R Bernards - Cancers, 2021 - mdpi.com
Simple Summary A major obstacle in the fight against cancer is the development of drug
resistance in response to therapy. Development of resistance can be facilitated by a small …
resistance in response to therapy. Development of resistance can be facilitated by a small …
[HTML][HTML] Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung …
D Planchard, PH Feng, N Karaseva, SW Kim, TM Kim… - ESMO open, 2021 - Elsevier
Background The phase III FLAURA2 (NCT04035486) study will evaluate efficacy and safety
of first-line osimertinib with platinum–pemetrexed chemotherapy versus osimertinib …
of first-line osimertinib with platinum–pemetrexed chemotherapy versus osimertinib …
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives
SE Rebuzzi, R Alfieri, S La Monica, R Minari… - Critical Reviews in …, 2020 - Elsevier
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improved clinical
outcome compared to chemotherapy in EGFR mutated advanced non-small cell lung cancer …
outcome compared to chemotherapy in EGFR mutated advanced non-small cell lung cancer …
[HTML][HTML] Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non …
R Saito, S Sugawara, R Ko, K Azuma, R Morita… - European Journal of …, 2023 - Elsevier
Background This multicenter phase 2 trial evaluated the safety and efficacy of osimertinib
and platinum-based chemotherapy (OPP) in patients with previously untreated EGFR …
and platinum-based chemotherapy (OPP) in patients with previously untreated EGFR …
Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
The current landscape of targeted therapies directed against oncogenic driver alterations in
non–small cell lung cancer (NSCLC) is expanding. Patients with EGFR-mutant NSCLC can …
non–small cell lung cancer (NSCLC) is expanding. Patients with EGFR-mutant NSCLC can …